MEK Inhibitor News and Research

RSS

Severe lymphatic disorder reversed through genetic sequencing and targeted treatment

Through genetic sequencing and targeted treatment, researchers from Children's Hospital of Philadelphia have resolved a severe lymphatic disorder in a young woman with kaposiform lymphangiomatosis (KLA), a complex and rare disorder that causes lymphatic vessels around the heart and lung to leak fluid, causing breathing difficulties, infections, and often death.

5 Oct 2020

Scientists identify key driver in BRAF inhibitor resistant melanoma

Targeted therapy with BRAF-MEK inhibitors is an effective treatment for patients with advanced melanoma that cannot be surgically removed or has spread to other areas of the body.

2 Sep 2020

First comparative data of encorafenib and paradox breaker inhibitors in BRAF mutant CRC

Oncotarget Volume 11, Issue 34 features Figure 1, "BRAF inhibitor-induced changes in cell viability," by Pickles, et al which reported that the BEACON CRC trial demonstrated a survival advantage over chemotherapy for a combination of targeted agents comprising the potent BRAF inhibitor encorafenib together with cetuximab and binimetinib.

26 Aug 2020

Combination therapy effective for patients with cholangiocarcinoma marked by BRAF mutations

In a Phase II trial led by researchers at The University of Texas MD Anderson Cancer Center, the combination of dabrafenib, a BRAF inhibitor, and trametinib, a MEK inhibitor, achieved a 51% overall response rate (ORR) in patients with cholangiocarcinoma marked by the BRAF V600E mutation.

18 Aug 2020

Pembrolizumab can improve outcomes in patients with metastatic melanoma

A new 10-year analysis led by Igor Puzanov, MD, MSci, FACP, Director of Early Phase Clinical Trials and Chief of Melanoma at Roswell Park Comprehensive Cancer Center and published today in the journal JAMA Oncology provides new insights into an important question.

17 Jul 2020

Study: Combination of melanoma drugs prevents cancer from growing or spreading

A first-of-its-kind randomized clinical trial offers strong and perhaps surprising evidence that a combination of two targeted melanoma drugs when given continuously keeps patients' cancer from growing or spreading longer when compared with intermittent treatment, according to study results to be presented at the 2020 virtual annual meeting of the American Association for Cancer Research.

27 Apr 2020

'Primitive' stem cells shown to replace and repair damaged blood vessels in the retina

Johns Hopkins Medicine scientists say they have successfully turned back the biological hands of time, coaxing adult human cells in the laboratory to revert to a primitive state, and unlocking their potential to replace and repair damage to blood vessels in the retina caused by diabetes.

9 Mar 2020

Study provides new insight into neurofibromin-deficient ER+ breast cancer

An international team of researchers led by scientists at Baylor College of Medicine has new insights into the function of neurofibromin, a tumor suppressor produced by the NF1 gene.

5 Mar 2020

Two-drug combination could be effective against malignant mesothelioma

Exposure to asbestos is the major risk factor for malignant mesothelioma, a type of aggressive cancer that mostly affects the pleura - the tissue that lines the lungs - and the peritoneum - the tissue that lines the abdomen. This has been known for decades, yet the molecular characterisation of mesothelioma is barely known and treatment options are scarce.

8 Jan 2020

New drug combo may improve pancreatic cancer therapy

A new study by scientists at Sanford Burnham Prebys Medical Discovery Institute have discovered a combination of two cancer-fighting drugs that successfully worked on pancreatic tumor in mice, shrinking them significantly, and paving the way for a speedy clinical trial designed to test their efficacy in humans.

18 Nov 2019

FDA grants acceptance to application for selumetinib as treatment for neurofibromatosis

AstraZeneca and MSD (Merck) announced today that the U.S. Food and Drug Administration (FDA) has granted acceptance to file status of its application for the MEK inhibitor selumetinib, for use in patients with plexiform neurofibromas, a common manifestation in the disease neurofibromatosis type one (NF1).

14 Nov 2019

Triplet therapy could benefit patients with BRAF-mutant metastatic colorectal cancer

Results presented today at the ESMO Congress 2019, Barcelona 27 September - 01 October, during the second Proffered Paper Session on Gastrointestinal tumors (colorectal) by VHIO's Director, Josep Tabernero, show that the triplet combination of the BRAF inhibitor, encorafenib, MEK inhibitor, binimetinib, and EGFR inhibitor, cetuximab, not only significantly improves overall survival but also increases objective response rates compared with standard of care in patients with BRAF V600E-mutant metastatic colorectal cancer.

30 Sep 2019

Study uncovers potential new treatment approach for lung cancer

Lung cancer is the second most common cancer found in both men and women. It is estimated there will be roughly 228,000 new lung cancer cases this year, and nearly 30% of those patients will have mutations in the KRAS pathway.

19 Aug 2019

New drug combination found to be effective against uveal melanoma in preclinical studies

Uveal melanoma is a very aggressive type of melanoma that affects the eye. It is a rare disorder, affecting an estimated 2,500 people in the United States each year.

8 Jul 2019

Gene mutation discovery leads to novel treatment for patient with severe lymphatic condition

Faced with a preteen boy in pain and struggling to breathe from a severe, deteriorating rare condition, researchers at Children's Hospital of Philadelphia identified the responsible gene mutation and harnessed that knowledge to develop a novel treatment that dramatically improved the problem.

2 Jul 2019

MEK Inhibitor News and Research

Severe lymphatic disorder reversed through genetic sequencing and targeted treatment

Scientists identify key driver in BRAF inhibitor resistant melanoma

First comparative data of encorafenib and paradox breaker inhibitors in BRAF mutant CRC

Combination therapy effective for patients with cholangiocarcinoma marked by BRAF mutations

Pembrolizumab can improve outcomes in patients with metastatic melanoma

Study: Combination of melanoma drugs prevents cancer from growing or spreading

'Primitive' stem cells shown to replace and repair damaged blood vessels in the retina

Study provides new insight into neurofibromin-deficient ER+ breast cancer

Two-drug combination could be effective against malignant mesothelioma

New drug combo may improve pancreatic cancer therapy

FDA grants acceptance to application for selumetinib as treatment for neurofibromatosis

Triplet therapy could benefit patients with BRAF-mutant metastatic colorectal cancer

Study uncovers potential new treatment approach for lung cancer

New drug combination found to be effective against uveal melanoma in preclinical studies

Gene mutation discovery leads to novel treatment for patient with severe lymphatic condition

Certain cancer drugs induce stem cell plasticity in colorectal cancer

Study finds promising new treatment for infants with Noonan Syndrome

New clinical genomic testing helps identify mutations that drive childhood melanoma

Study uncovers a protein involved in lung cancer treatment resistance

Researchers discover how MAPK translocation leads to drug resistance in melanoma

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News